Paragon Associates & Paragon Associates II Joint Venture’s DiaMedica Therapeutics DMAC Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.92M	Hold	875,000	–	–	8.05%	4
2025 Q4	$6.96M	Hold	875,000	–	–	14.39%	3
2025 Q3	$6.01M	Buy	875,000 +225,000	+35%	+$1.22M	10.72%	4
2025 Q2	$2.54M	Buy	650,000 +50,000	+8%	+$195K	4.03%	11
2025 Q1	$2.27M	Buy	600,000 +85,216	+17%	+$487K	5.33%	7
2024 Q4	$2.8M	Buy	514,784 +32,170	+7%	+$152K	6.46%	6
2024 Q3	$2.02M	Hold	482,614	–	–	3.63%	10
2024 Q2	$1.42M	Sell	482,614 -17,386	-3%	-$47.7K	3.48%	10
2024 Q1	$1.39M	Hold	500,000	–	–	2.47%	15
2023 Q4	$1.42M	Buy	500,000 +30,000	+6%	+$74.2K	3.26%	11
2023 Q3	$1.21M	Buy	470,000 +145,000	+45%	+$466K	3.97%	7
2023 Q2	$1.4M	Buy	+325,000	New	+$789K	2.87%	9

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's DMAC Position: Q1 2026 in Review

Paragon Associates & Paragon Associates II Joint Venture held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 875,000 shares worth $5.92M. The position accounts for 8.05% of the portfolio, ranked #4.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in DMAC in Q2 2023 and has held it in 12 quarters since. The position peaked at $6.96M in Q4 2025. 99 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Paragon Associates & Paragon Associates II Joint Venture held 875,000 shares of DiaMedica Therapeutics worth $5.92M as of Q1 2026.
Paragon Associates & Paragon Associates II Joint Venture left its DiaMedica Therapeutics share count unchanged in Q1 2026.
DiaMedica Therapeutics made up 8.05% of Paragon Associates & Paragon Associates II Joint Venture's portfolio in Q1 2026, its #4 holding.
Paragon Associates & Paragon Associates II Joint Venture first reported a position in DiaMedica Therapeutics in Q2 2023 and has held it in 12 quarters since.
Paragon Associates & Paragon Associates II Joint Venture's DiaMedica Therapeutics position peaked at $6.96M in Q4 2025.
99 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q1 2026, filed 15 May 2026.